Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 +8.60 0.06%
S&P 500 1,649.64 -0.87 -0.05%
Nasdaq 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Exchange: NASDAQ CM
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

Ventrus Biosciences Inc

+ Add to Watchlist

VTUS:US

2.6600 USD 0.1000 3.62%

As of 16:00:00 ET on 05/24/2013.

Company Profile for Ventrus Biosciences Inc (VTUS)

Ventrus Biosciences Inc. is a development stage pharmaceutical company. The Company is focused on late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. Ventrus's lead products are topical treatments for hemorroids, which targets a specific serotonin receptor.

Contact Information

Ventrus Biosciences Inc

99 Hudson Street 5th Floor
New York, NY 10013
United States
Phone: 1-212-554-4267
Fax: 1-212-554-4314

Key Executives for Ventrus Biosciences Inc (VTUS)

Russell H EllisonChairman/President/CEODavid J BarrettChief Financial Officer

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil